Georgia Bio Executive Committee

Patty Fritz
Chair, Georgia Bio
Vice President, U.S. Corporate Affairs, UCB, Inc.

Patty Fritz is vice president, U.S. Corporate Affairs for UCB, Inc, overseeing policy, government affairs, advocacy, patient engagement, communications and UCBCares®. Patty leads efforts to create value for patients and their families through strategic engagement and positively influencing the healthcare environment and policy landscape. 

At UCB, everything we do starts with one simple question: “how will this create value for people living with severe diseases?” In her Corporate Affairs role, Patty finds opportunities to better understand the unique needs of patients, so we can continue delivering value. She is a champion of innovative projects to spotlight the importance of access and care for people living with severe diseases. Recent efforts Patty has led include collaborations with the VA Epilepsy Centers of Excellence, PatientsLikeMe®, Emory University, Georgia Tech and IBM.

Having been with UCB for more than 20 years, Patty has made a significant impact in different leadership roles including Regulatory Affairs, Operational Excellence, Government Affairs and Policy. She managed teams and inspired colleagues as UCB transformed from a primary care company to a specialty biopharma pharmaceutical leader focused on severe diseases. Patty led the regulatory efforts for UCB’s first product filing - Keppra® (levetiracetam) - and oversaw the FDA approval process for many of UCB’s other products including Lortab™ (hydrocodone), Xyzal® (levocetirizine), Cimzia® (certolizumab pegol) and Vimpat® (lacosamide). She also championed and was a driving force behind the establishment of UCB’s Women in Leadership initiative. 

Outside of UCB, Patty serves as chair of the board of directors for Georgia Bio and as a member of The Carter Center Board of Councilors. 

Patty holds a master’s degree in health care policy and administration from Mercer University (Atlanta, Ga.) and a Bachelor of Science degree in management and technology from the University of Maryland (Laurel, Md.). Patty is also a graduate of Summers County School of Nursing (Hinton, W.Va.).

H. Lee Herron, DVM
Vice Chair, Georgia Bio
Vice President, Venture Development, Georgia Research Alliance (GRA)

Dr. Lee Herron joined the Georgia Research Alliance in 2008 to direct its venture development program, which has launched 180 companies and attracted more than $1 billion in equity investment.

GRA supports universities in forming new companies around their discoveries, providing seed funds and access to experienced mentoring and expert consulting. As vice president of venture development, Lee does everything from reviewing business proposals to meeting with faculty scientists. He often walks university halls and drops by labs, gaining an insider’s perspective on the newest innovations that could lead to a new company.

Lee helps GRA portfolio companies prepare a strong pitch to investors. Drawing on his own 17 years of entrepreneurial experience, he ensures that companies adopt a sound business strategy and operational plans. As Lee explains, it’s not enough to just have a brilliant idea. “Successful entrepreneurs must be comprehensive in their understanding of what questions to ask.” Lee guides faculty and entrepreneurs in figuring out the right questions, a role that has earned him the nickname “Start-up Sherpa.” 

Previously, Lee managed the biosciences division of Georgia Tech’s Advanced Technology Development Center (ATDC), advising early stage life science companies. In his earlier career, he founded SeaLite Sciences, Inc., a company that developed and commercialized diagnostic products and molecular biology reagents derived from a light-emitting protein found in jellyfish. He was also a founding team member of three other bioscience companies: Biopool International, Inc., CytRx Corporation, and Theragenics Corporation. Lee also worked with German biotech company BRAHMS AG to establish its North American operations.

Today, Lee serves on the boards of Georgia Bio and Southeast Bio, and is a special advisor to the Executive Committee of Georgia’s Bio/Med Investor Network. Lee serves on numerous advisory committees, and he was Chairman of the 2017 Georgia Bio Innovation Summit.

Lee holds a Doctor of Veterinary Medicine degree from The University of Georgia. He also studied experimental pathology at Emory University.

Jay Yadav, M.D.
Immediate Past Chair, Georgia Bio
Founder & CEO, MiRus LLC

Jay S. Yadav, M.D., is the Founder and CEO of MiRus, LLC, an orthopaedic and spine company. He was the founder of CardioMEMS (acquired by St. Jude Medical), Angioguard (acquired by JNJ) and initial investor and director of SMART Therapeutics (acquired by Boston Scientific). Dr. Yadav is a director of several private life sciences and technology companies. He is a Director of Georgia Bio, the Global Center for Medical Innovation (GCMI), the Bio/Med Investor Network, the Southeast Medical Device Association (SEMDA) and Beacon College. He is on the Entrepreneurship Advisory Board of the Yale School of Management.

Dr. Yadav has authored two books, over two hundred publications, and holds over forty patents. He has received numerous honors including the American Heart Association Top Ten Scientific Advances for 2003, Ellis Island Medal of Honor for 2004, Southeast Medical Device Association Entrepreneur of the Year Award for 2010, Phoenix Award for Medical Devices 2011, Association of Telecom Professionals Award 2011, Ernst and Young Entrepreneur of the Year for Healthcare (Southern Region) for 2011, Association for Corporate Growth Deal of the Year 2014 and Georgia Bio Deal of the Year 2014.

Heather Mullins, CPA
Partner, Frazier & Deeter

Heather Mullins is an Audit Partner in the Assurance and Advisory Services Practice of Frazier & Deeter. Prior to joining Frazier & Deeter in 2005, Heather spent five years in the audit practice for one of the Big Four accounting firms where she served large public companies and private companies in the middle market. Heather brings over 22 years of experience in public accounting. Her effective problem solving, leadership and communication skills strengthen her ability to provide insights and help her clients reach sound and practical conclusions.

Heather has worked with a variety of institutions, assisting clients with development of policies and procedures and internal controls over financial reporting, as well as performing and managing financial statement reviews and audits and other attestation engagements. Heather works mainly with middle market companies in the private sector, heading up Frazier & Deeter’s Healthcare Practice, as well as focusing on manufacturing and distribution companies, service providers, financial services companies and technology companies.

Heather works closely with Frazier & Deeter’s audit methodology to ensure quality and consistency of procedures throughout the assurance practice. In addition to leading the Healthcare Practice, Heather is a member of the firm’s Technology Industry Group, Manufacturing & Distribution Industry Group and Service Industry Group.

William L. Warren 
Corporate Counsel
Partner - IP Practice Group Leader, Eversheds Sutherland LLP

Bill Warren advises clients on strategic intellectual property issues primarily in the life sciences sector, but also in a number of other industries. The majority of his practice focuses on patents related to biotechnology, medical device and pharmaceutical inventions. Bill prosecutes patents, counsels clients on patent validity and infringement issues and prepares product clearance opinions and development strategies. He also negotiates technology transfer licensing agreements and conducts intellectual property due diligence. Bill protects patents, trademarks and copyrights and, when necessary, participates in litigating intellectual property issues. Bill currently leads Sutherland’s Intellectual Property Practice Group and is chair of the firm’s biotechnology & life sciences team. 

Jamie Hennessy
Audit & Finance Committee Chair
Controller, Private Wealth Management, SunTrust Bank

Having grown up in England, Jamie attended the University of Bath where he studied for a Masters in Pharmacology. During this 4 year accelerated course, he spent a year working at Novartis just outside of London, focusing on developing a treatment for Idiopathic Pulmonary Fibrosis. After graduating, Jamie joined Grant Thornton, an International CPA firm, with the intention of working with companies across all industries to help them with their business needs. Having spent 3 years in the Cardiff office of Grant Thornton, Jamie took an opportunity to move with Grant Thornton to Sydney, Australia, during which he became an active member of AUSBiotech (the GA BIO equivalent in NSW, Australia) and helped a number of his clients in the Pharma space. After nearly 3 years in Australia, Jamie moved with Grant Thornton again to Atlanta where he spent 4 years prior to joining SunTrust Bank as the Controller of their Private Wealth Management division. 

Russell Medford, MD, Ph.D.
Governance, Nominating & Compensation Committee Chair
Managing Partner, Salutramed Group

Russell M. Medford, MD, PhD, Managing Partner is a senior biotechnology executive with extensive private and public company experience as Chief Executive Officer and Board member of multiple biotechnology and other health related companies, organizations and research institutes. From 1995 to 2009, Dr. Medford served as co-founder, President, CEO and Director of publicly-held AtheroGenics, Inc (Nasdaq: AGIX) and from 2009 to 2012 CEO and Chairman of Salutria Pharmaceuticals, LLC. He was a founding Board Director of publicly-held Inhibitex, Inc. (Nasdaq: INHX) until it was acquired by Bristol-Myers-Squibb in 2012 for $2.5 billion. He has had extensive experience leading companies and organizations engaged in comprehensive therapeutic drug research and development, developing multiple, novel, first-in-man clinical candidates for the treatment of cardiovascular disease, diabetes and arthritis, conducted multiple phase I, II and III clinical studies involving over 400 clinical trial sites in 12 countries, including the US, UK, Canada, South Africa, India, Russia, Eastern Europe and India involving more than 7000 patients, executed multiple strategic partnerships with major pharmaceutical companies including Schering-Plough, Fujisawa and AstraZeneca, as well as building a commercial-scale, manufacturing plant for lead, small-molecule pharmaceutical agents. He has extensive experience in both the private and public financial markets including initial public offerings (IPO) raising over $500 million for corporate, clinical development and research programs. He has served on multiple private company Boards including Transcardiac Therapeutics, Inc., Somatocor, Inc. and EmTech Bio. He is a board-certified physician, an inaugural Fellow of the Council on Basic Cardiovascular Sciences of the American Heart Association, a member of the executive committee and former Chairman of GeorgiaBio, a member of Biotechnology Industry Organization’s (BIO) Board of Directors, Emerging Companies Section Governing Board and Health Science Governing Board, Co-Chairman of BIO’s Bioethics Committee and served as Chairman of the BIO's 2009 International Convention Steering Committee. Dr. Medford is a past member of the Advisory Council of the National Heart, Lung and Blood Institute and currently serves on the Board of Trustees of the National Health Museum and Chairman of the External Advisory Board for the Petit Institute of Bioscience and Bioengineering of the Georgia Institute of Technology. He has received numerous awards including the Ernst and Young Entrepreneur of the Year Award (Southeast), the Biomedical Industry Growth Award (Georgia Bio), CATALYST Magazine's Top 50 Entrepreneurs and the SCRIPP Best Partnership Alliance (London). Dr. Medford also serves as Chairman of Artetude Gallery, Inc., a private, North Carolina contemporary fine art company based in Asheville. Dr. Medford was an Associate Professor of Medicine, Director of Molecular Cardiology and Adjunct Clinical Professor of Medicine at the Emory University School of Medicine where he founded Atherogenics, Inc. He received a B.A. from Cornell University, and a M.D. with Distinction and a Ph.D. in Molecular and Cell Biology from the Albert Einstein College of Medicine, completing his residency and cardiology fellowship at Harvard’s Beth Israel and Brigham and Women’s Hospitals where he also served on the faculty of Medicine. He publishes widely and holds over 16 U.S. and international patents.

Holly Bates Snow
Policy & Advocacy Committee Chair
State Government Affairs Sr. Manager, South, Amgen

Holly joined Amgen in 2013 and is responsible for representing Amgen’s interests before state legislative, regulatory and executive branches in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, and Tennessee.

Prior to joining Amgen, Holly was Vice President for a leading health system in Georgia, Piedmont Healthcare for eight years. This system included 5 acute care hospitals, more than 10,000 employees, and some 1000 physicians (350 of whom were employed). . In this role, Holly was responsible for overseeing all aspects of federal, state, and local government relations for the system, which included policy development, lobbying, regulatory representation before local, state, and U.S. officials. Her other responsibilities included coalition building with other hospitals and various organizations such as the Georgia Hospital Association, Georgia Chamber of Commerce, Medical Association of Georgia, and patient groups. 

Prior to Piedmont, Holly was Vice President of Government Affairs for the Georgia Hospital Association where she worked for 15 years. She developed and executed strategic plans and lobbied interests of for-profit, non-profit, and government acute care, rehab, and substance abuse hospitals before the U.S. Congress, Georgia General Assembly, governor, appointed and elected agencies. She also worked with business, civic and healthcare organizations and coalitions to influence policy positions to support and enhance hospital initiatives. 

She started her career in public relations and government affairs with a family owned firm in Atlanta where she served as Vice President for 10 years. In this capacity, she worked closely with the media, wrote speeches, developed and executed media/and public relations campaigns. Additionally, she represented various clients before the Georgia General Assembly including Morehouse School of Medicine and Grady Hospital (the state’s largest public/indigent care facility), 

Currently, Holly services as Vice Chair of the PhRMA Task Force in GA, Chair of the Georgia Bio government affairs committee, and Board of Directors member for BIO FL where she also serves on the government affairs committee. 

Holly was graduated with Bachelor of Arts degrees in communications and political science from Tulane University and Newcomb College in New Orleans. She is an avid exercise and sports enthusiast as well as an apiarist when she is not trying to keep her youngest son out of jail and her oldest son in college. 

Chaarles Fogelgren
2016-2018 Georgia BioEd Institute Chair
VP and General Manager, med fusion, LLC

Mr. Fogelgren is the VP and GM of the Clinical Trials Division at med fusion, LLC, a Dallas, TX based reference lab. Prior to joining med fusion, Mr. Fogelgren was Global Head and Senior Director of Laboratory Data Management at Quintiles Central Laboratories (now Q2 Solutions) where he led the turnaround and globalization of the team with sites in India, Europe, and North America that performed all master and protocol specific programming and validation, data integration, and data delivery. He has spent almost 20 years in pharmaceutical development from early research to IND directed toxicology. In addition, he has been involved in the development of several security and data mining technologies for government and life science applications. Mr. Fogelgren received his undergraduate degree in Anthropology from The George Washington University and his Master of Business Administration from the Kenan-Flagler Business School at the University of North Carolina. He is presently the Chair of the Georgia Bio Ed Institute.

Tiffany Wilson
2018 Georgia Bio Innovation Summit Chair

Tiffany has spent more than 15 years bringing innovative medical technology from benchtop to bedside. She joined GCMI in 2011 to lead its startup phase, establishing overall strategic vision, building strategic relationships and bringing together key stakeholders of the medical device ecosystem. Her strong background in medical devices, commitment to fostering innovation and understanding of business strategies have propelled her into a leadership role in the Southeast and brought her into the national spotlight. Wilson joined GCMI from Scientific Intake, where she served as the Vice President of Business Development and Strategy, evaluating marketing and distribution opportunities and driving product development projects for the global obesity market. Prior to Scientific Intake, she was Vice President of Corporate Strategy and Finance at ACell, Inc., a regenerative medicine and tissue engineering company based in Columbia, Maryland. At ACell, she led a broad range of initiatives including corporate finance, investor relations, strategic and operational planning, business development, regulatory, and reimbursement. Tiffany serves as Past-President of the Board of the Southeast Medical Device Association (SEMDA), Founding Member of Medtech Women @ SEMDA, Chair of the T3 Labs Advisory Board, and the Georgia Bio Board of Directors. She is a Member of the National Advisory Council on Innovation and Entrepreneurship (NACIE) at the U.S. Department of Commerce. She led the Sponsorship Committee of the 2013 SEMDA Conference and has served as the Co-Chair of the Medical Device Subcommittee of the Metro Atlanta Chamber Bioscience Leadership Council. In 2015 Tiffany received the prestigious Georgia Bio Community Award and in 2017 was presented with the Industry Growth Award, the highest honor bestowed each year by Georgia Bio.  She was recently recognized by Inc. Magazine as one of “17 Inspiring Women to Watch in 2017” and one of Becker Hospital Review’s “110 Women in Medtech to Know in 2017”.